Advances in the study of structural modifications of multi-target anticancer drug sorafenib

Sorafenib, the first oral multikinase inhibitor, can inhibit several kinases involved in tumor proliferation and angiogenesis including Raf, VEGFR, PDGFR, kit and so on. Due to the advantages of multi-mechanisms, broad-spectrum anticancer potency, and well-tolerated results in combination trials, mo...

Full description

Saved in:
Bibliographic Details
Published inYao hsüeh hsüeh pao Vol. 47; no. 9; p. 1111
Main Authors Yao, Jian-Wen, Sun, Wei, Chen, Jing, Xu, Wen-Fang
Format Journal Article
LanguageChinese
Published China 01.09.2012
Subjects
Animals
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - chemistry
Cell Line, Tumor
Humans
Molecular Structure
Neoplasms - drug therapy
Neoplasms - pathology
Neovascularization, Pathologic - prevention & control
Niacinamide - analogs & derivatives
Niacinamide - chemical synthesis
Niacinamide - chemistry
Phenylurea Compounds - chemical synthesis
Phenylurea Compounds - chemistry
Protein Kinase Inhibitors - chemical synthesis
Protein Kinase Inhibitors - chemistry
Structure-Activity Relationship
Online AccessGet more information

Cover

More Information
Summary:Sorafenib, the first oral multikinase inhibitor, can inhibit several kinases involved in tumor proliferation and angiogenesis including Raf, VEGFR, PDGFR, kit and so on. Due to the advantages of multi-mechanisms, broad-spectrum anticancer potency, and well-tolerated results in combination trials, more and more researchers have focused on the optimization of sorafenib in order to develop novel multi-targeted anticancer drugs. The present paper reviews the development of modification of sorafenib in recent years from two aspects: bio-isosterism and scaffold hopping. The structure-activity relationship (SAR) of these compounds is also summarized.
ISSN:0513-4870